Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.42 |
| ▸ | PPP5C | P53041 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14153818 | 0.91 | GBA1 (0.44) | GBA1PPP5CGLB1GBA2 | |
| SCHEMBL17342220 | 0.86 | GBA1 (0.42) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL16769690 | 0.86 | GBA1 (0.42) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL15948615 | 0.86 | GBA1 (0.42) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL14210158 | 0.85 | GBA1 (0.53) | GBA1PPP5CEPHX2GLB1GBA2 | |
| SCHEMBL6852788 | 0.84 | GBA1 (0.41) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL17859520 | 0.79 | GBA1 (0.41) | GBA1PPP5CTSHREPHX2SMN1; SMN2 | |
| SCHEMBL16449108 | 0.79 | ADRB2 (0.35) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL27098020 | 0.79 | ADRB2 (0.35) | GBA1PPP5CTSHREPHX2ALDH1A1 | |
| SCHEMBL25578790 | 0.79 | EPHX2 (0.38) | GBA1PPP5CTSHREPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227635-B2 | Apparatus and method for carrying out multiple reactions | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20090299102-A1 | APPARATUS AND METHOD FOR CARRYING OUT MULTIPLE REACTIONS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299102-A1 | APPARATUS AND METHOD FOR CARRYING OUT MULTIPLE REACTIONS | DDO, APEX1, MMAB | GBA1 969/4885PPP5C 3786/4885TSHR 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.